Skip to NavigationSkip to content

News

AbbVie has terminated a Phase 3 study of the efficacy of Depatux-M in the treatment of newly diagnosed glioblastoma (GBM) in patients whose tumours...
Boehringer has announced that Pradaxa has failed to meet its primary endpoint in its Phase 3 study, proving unable to show superiority over...
Takeda has unveiled exploratory data on Entyvio, demonstrating its superiority over AbbVie’s Humira in achieving remission in moderately to...
Sandoz has revealed that its generic statin rosuvastatin, known in its branded incarnation as Crestor, has been given approval in China from the...
The expanded indication relates specifically to adult patients who are not eligible for stem cell transplant and only where thalidomide cannot be...
Roche has unveiled new Phase 1/2 data for its selective tyrosine kinase inhibitor entrectinib, demonstrating its ability to shrink recurrent or...
Gilead, Janssen and BMS accused of forging anticompetitive deal; Novartis buy Takeda's dry eye drug Xiidra for $5.3 billion; NHS England to pay for...
The FDA has announced its approval of Pfizer’s anticoagulant injection Fragmin (dalteparin sodium) for subcutaneous use as a treatment to reduce...
US Representative Alexandria Ocasio-Cortez tore into Gilead CEO Daniel O’Day on Thursday, over the firm’s nearly $2,000 price tag on PrEP drug,...
Twitter will now present users with a pinned tweet directing them towards reliable information on vaccines, according to a blog post from Del...
Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches